{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Inozyme Pharma, Inc. technically bullish or bearish?
As of April 30, 2025, the trend is mildly bearish, with daily moving averages indicating bearishness, mixed signals from the weekly MACD and RSI, and conflicting Bollinger Bands suggesting short-term bearish strength.
Who are in the management team of Inozyme Pharma, Inc.?
As of March 2022, the management team of Inozyme Pharma, Inc. includes Dr. Douglas Treco (Independent Chairman), Mr. Axel Bolte (President and CEO), and several Independent Directors: Ms. Sarah Bhagat, Mr. Reinaldo Diaz, Dr. Martin Edwards, and Dr. Robert Hopfner.
What does Inozyme Pharma, Inc. do?
Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases related to abnormal mineralization, specifically targeting ENPP1 and ABCC6 deficiencies. As of March 2025, it has a market cap of $257.28 million and reported a net profit loss of $28 million.
How big is Inozyme Pharma, Inc.?
As of Jun 18, Inozyme Pharma, Inc. has a market capitalization of 257.28 million and reported net sales of 0.00 million with a net profit of -106.71 million over the last four quarters. Shareholder's funds were 57.83 million, and total assets were 123.18 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
